Melphalan, an important DNA damage agent, is one of the most widely used and effective drugs in the treatment of multiple myeloma. Unfortunately, although most patients respond to standard and high dose melphalan therapy, eventually patients will acquire drug resistance. Evidence has accumulated to suggest that DNA damage repair pathway called FANC/BRCA, which was first discovered in Fanconi anemia (FANC) patients may contribute to the melphalan resistance in multiple myeloma. The goal of my proposed study is to verify that the FANC/BRCA pathway is important melphalan-resistant human myeloma cells. This study will enhance our understanding of why patients become resistant to melphalan, and possible means of improving the therapeutic response to melphalan.